Zoster Vaccine Recombinant, Adjuvanted
| Brand name | Shingrix |
|---|---|
| Active ingredient | Zoster Vaccine Recombinant, Adjuvanted |
| Strength | 50UG |
| Dosage form | Injection |
| Route | Intramuscular |
| Modality | Biologic |
| FDA approval | July 2025 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.